{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-059454","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.813562+00:00","generated_at":"2026-06-15T02:36:18.656562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avenue Therapeutics Q1 net loss $7.5M; advances AJ201 and IV Tramadol programs","bullets":["Net loss of $7.5M ($1.37 per share) vs $2.9M loss ($2.05 per share) in Q1 2022.","Cash and equivalents $8.2M at March 31, 2023, up from $6.7M at December 31, 2022.","R&D expenses $1.2M plus $4.2M in licenses acquired (AJ201) vs $1.8M prior-year period.","Entered exclusive license for AJ201 (SBMA treatment); Phase 1b/2a trial ongoing; FDA orphan drug designation.","FDA agreed on most aspects of IV Tramadol safety confirmatory trial protocol; pending final statistical analysis plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-059454","json":"https://secwatch.observer/filing/0001104659-23-059454.json","markdown":"https://secwatch.observer/filing/0001104659-23-059454.md","text":"https://secwatch.observer/filing/0001104659-23-059454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/0001104659-23-059454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/tm2315281d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:36:18.656562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59592784558e8600964cd061ed7c1ff992400147","claim":"AVENUE THERAPEUTICS, INC. reported the first quarter ended March 31, 2023 results: net income $7.5 million, or $1.37 per share, EPS $1.37 per share.","evidence_excerpt":"Net loss attributable to common stockholders for the first quarter of 2023 was $7.5 million, or $1.37 per share, compared to a net loss of $2.9 million, or $2.05 per share, for the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465923059454/0001104659-23-059454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"$7.5 million, or $1.37 per share"},{"label":"EPS","value":"$1.37 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}